Marc Lesnick, Ph.D.

Regulatory

Marc Lesnick, Ph.D., is the Sr. Vice President of Regulatory Affairs at QED Therapeutics.  Dr. Lesnick brings over 20 years of product development and regulatory affairs knowledge and expertise, with multiple successful marketing applications in the United States and Europe. Prior to joining QED he served as the Sr. Vice President of Regulatory Affairs and Quality at Cascadian Therapeutics, a breast cancer oncology company, which was successfully acquired by Seattle Genetics in 2018. Dr. Lesnick was the Senior Vice President, U.S. Regulatory Affairs, Global Development Projects at Shionogi, Inc., where he managed regulatory strategy for oncology, infectious disease and other therapeutic area programs, led the filing of a New Drug Application (NDA) for Symproic® (naldemedine) and oversaw the approval and launch of Osphena® (ospemifene). At Optimer Pharmaceutics, he served as the Vice President of Regulatory Affairs, and led the successful submission and approval of their lead product Dificid® (fidaxomicin) in the US, EU and Canada. Prior to joining Optimer Pharmaceuticals, Dr. Lesnick held a position at the NIH within the NIAID. Dr. Lesnick’s academic experience includes an appointment as research faculty at the University of California San Diego, School of Medicine, following his Ph.D. from the University of Oregon.